Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that...
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses...